Arabic Arabic English English French French German German
dark

Sesen Bio and Qilu Pharmaceutical Announce Enrollment of First Patient in Clinical Trial for Vicineum™ in China

Sesen Bio announced today that the first patient has been enrolled in China in the clinical trial to assess the efficacy and safety of Vicineum in patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Neuspera Medical Announces Close of a $65M Series C Equity Financing

Next Post

4 Tips On How To Become A CER Writer And Benefit From It

Related Posts
Total
0
Share